Related references
Note: Only part of the references are listed.TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer
Samuel R. Denmeade et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts
Hung-Ming Lam et al.
EUROPEAN UROLOGY (2020)
Abiraterone acetate plus prednisone in patients with newly Croatia& diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
Karim Fizazi et al.
LANCET ONCOLOGY (2019)
Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage
Payel Chatterjee et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study
Benjamin A. Teply et al.
LANCET ONCOLOGY (2018)
Transient exposure to androgens induces a remarkable self-sustained quiescent state in dispersed prostate cancer cells
Anh Thu Bui et al.
CELL CYCLE (2017)
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study
Michael T. Schweizer et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Conversion of Androgen Receptor Signaling From a Growth Suppressor in Normal Prostate Epithelial Cells to an Oncogene in Prostate Cancer Cells Involves a Gain of Function in c-Myc Regulation
Donald J. Vander Griend et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Androgen Suppresses the Proliferation of Androgen Receptor-Positive Castration-Resistant Prostate Cancer Cells via Inhibition of Cdk2, CyclinA, and Skp2
John M. Kokontis et al.
PLOS ONE (2014)
Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
Maha Hussain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Of mice and men-warning: Intact versus castrated adult male mice as xenograft hosts are equivalent to hypogonadal versus abiraterone treated aging human males, respectively
J. P. Michiel Sedelaar et al.
PROSTATE (2013)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer
John T. Isaacs et al.
PROSTATE (2012)
Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc
Chih-Pin Chuu et al.
CANCER SCIENCE (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
Chih-Pin Chuu et al.
JOURNAL OF BIOMEDICAL SCIENCE (2011)
Bipolar Androgen Therapy: The Rationale for Rapid Cycling of Supraphysiologic Androgen/Ablation in Men With Castration Resistant Prostate Cancer
Samuel R. Denmeade et al.
PROSTATE (2010)
Tissue Culture Media Supplemented With 10% Fetal Calf Serum Contains a Castrate Level of Testosterone
J. P. Michiel Sedelaar et al.
PROSTATE (2009)
Stabilizing androgen receptor in mitosis inhibits prostate cancer proliferation
Donald J. Vander Griend et al.
CELL CYCLE (2007)
Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells
Ivan V. Litvinov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice
CP Chuu et al.
CANCER RESEARCH (2005)
Molecular determinants of resistance to antiandrogen therapy
CD Chen et al.
NATURE MEDICINE (2004)
Molecular characterization of human prostate carcinoma cell lines
A van Bokhoven et al.
PROSTATE (2003)
Spectral karyotype (SKY) analysis of human prostate carcinoma cell lines
A van Bokhoven et al.
PROSTATE (2003)
Studies on prostatic cancer - I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
C Huggins et al.
JOURNAL OF UROLOGY (2002)
Share Paper
